Shimura Hideki, Hattori Nobutaka
Department of Neurology, Juntendo University Urayasu Hospital.
Brain Nerve. 2017 Feb;69(2):159-165. doi: 10.11477/mf.1416200656.
Currently, treatment of Parkinson's disease aims at alleviating its symptoms. However development of disease-modifying drugs has been a remarkable advancement in recent years. Furthermore, clinical trials of immunotherapy against α-synuclein, a protein involved in the pathogenesis of and lesion expansion in Parkinson's disease, have been initiated. Here, the disease-modifying treatment for patients with Parkinson's disease including the current α-synuclein immunotherapy, gene therapy, protein injection therapy, and cell transplantation therapy, has been reviewed.
目前,帕金森病的治疗旨在缓解其症状。然而,近年来,疾病修饰药物的研发取得了显著进展。此外,针对α-突触核蛋白(一种参与帕金森病发病机制和病变扩展的蛋白质)的免疫疗法的临床试验已经启动。在此,对帕金森病患者的疾病修饰治疗进行了综述,包括目前的α-突触核蛋白免疫疗法、基因疗法、蛋白质注射疗法和细胞移植疗法。